(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 12.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Veracyte's revenue in 2026 is $517,145,000.On average, 16 Wall Street analysts forecast VCYT's revenue for 2026 to be $46,743,803,436, with the lowest VCYT revenue forecast at $44,704,900,199, and the highest VCYT revenue forecast at $48,473,613,391. On average, 16 Wall Street analysts forecast VCYT's revenue for 2027 to be $52,517,252,741, with the lowest VCYT revenue forecast at $49,179,998,807, and the highest VCYT revenue forecast at $55,314,983,956.
In 2028, VCYT is forecast to generate $57,953,003,732 in revenue, with the lowest revenue forecast at $52,748,476,764 and the highest revenue forecast at $60,713,389,486.